読み込み中
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
前日終値
$0.8769
−$0.0183 · -2.04%
日中の時刻はETです。市場データは遅延する場合があります。
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
日中レンジ
現在 $0.8769
52週レンジ
現在 $0.8769
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
25
割高
センチメント
71
強気
リスク
75
高リスク
モメンタム
30
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
日中レンジ
現在 $0.8769
52週レンジ
現在 $0.8769
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | — | — | — | 23.5万 USD | — |
| 粗利益 | — | — | — | −23.5万 USD | — |
| 研究開発 | 3718.7万 USD | 4167.6万 USD | 3719.6万 USD | 3032.4万 USD | 1857.2万 USD |
| 販売・一般管理 | 1061.2万 USD | 1229万 USD | 1352.8万 USD | 1322.7万 USD | 1002.6万 USD |
| 営業費用 | 4779.9万 USD | 5396.6万 USD | 5072.4万 USD | 4331.6万 USD | 2859.8万 USD |
| 受取利息 | — | — | 2480.5万 USD | 2221.7万 USD | 1744.7万 USD |
| 支払利息 | 1.3万 USD | 2.5万 USD | 2.7万 USD | 2.8万 USD | 89.3万 USD |
| 減価償却費と償却費 | 22.8万 USD | 26.6万 USD | 25.2万 USD | 23.5万 USD | 9.3万 USD |
| 営業利益 | −4779.9万 USD | −5396.6万 USD | −5072.4万 USD | −4355.1万 USD | −2859.8万 USD |
| 純利益 | −2348.7万 USD | −3397.1万 USD | −2578.8万 USD | 75.7万 USD | −1171.6万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$3.00
上昇余地（242.11%）AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
